









RESEARCH LETTER

Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition in Patients With Acute Anterior Myocardial Infarction: Final 1-Year Outcomes of the Randomized CARE-AMI Trial

Thomas Pilgrim , MD, MSc; Benedikt Bernhard , MD; Monika Fürholz, MD; René Vollenbroich, MD, MPP; Flora Babongo Bosombo, PhD; Sylvain Losdat, PhD; Nicole Reusser, RN; Stephan Windecker , MD; Stefan Stortecky , MD, MPH; George C. M. Siontis , MD, PhD; Lukas Hunziker , MD; Jonas Lanz , MD, MSc; Stephan Dobner , MD, PhD

Left ventricular (LV) remodeling after ischemic injury is catalyzed by dysregulation of G-protein–coupled receptor kinases (GRKs).¹ Preclinical studies suggest that competitive inhibition of GRK2 mitigates the extent of myocardial fibrosis and improves LV function.² Paroxetine, a selective serotonin reuptake inhibitor, selectively inhibits GRK2 and has been shown to attenuate maladaptive remodeling in a mouse model.³ The CARE-AMI (Paroxetine-Mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction) trial was an investigator-initiated, double-blind, randomized controlled trial investigating the potential of paroxetine-mediated GRK2 inhibition compared with placebo to reduce adverse LV remodeling in patients with acute anterior ST-segment-elevation myocardial infarction (STEMI) with a LV ejection fraction (LVEF) \leq 45% (ClinicalTrials.gov identifier: NCT03274752). The study protocol was approved by the local ethics committee, and all participants provided written informed consent before randomization. Anonymized data and materials have been made

publicly available at the Bern Open Repository and Information System and can be accessed at <https://boris.unibe.ch>. Eligibility criteria, end point definitions, and details of randomization, masking, and study conduct have been described elsewhere.⁴ The primary end point results were assessed by means of cardiac magnetic resonance imaging at 12 weeks after STEMI and have been reported previously.⁴ Herein, we report the final clinical and echocardiographic outcomes at 1 year. LV volume and ejection fraction were measured with the use of the biplane Simpson method. LV global longitudinal strain was assessed by speckle-tracking echocardiography. Outcome assessors were blinded to treatment allocation. *P* values for differences in categorical variables were computed using χ^2 or Fisher exact test. We used the Wilcoxon rank sum tests to compare patient-level changes from baseline to follow-up within each treatment group and between the experimental and the control group. Only patients with available serial echocardiographic data were considered for the primary analysis. A total of 50 patients

Key Words: GTP-binding proteins ■ humans ■ myocardial infarction ■ paroxetine

Correspondence to: Thomas Pilgrim, MD, MSc, Department of Cardiology, Inselspital Bern University Hospital, CH-3010 Bern, Switzerland. Email: thomas.pilgrim@insel.ch

For Sources of Funding and Disclosures, see page 3.

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

Table 1. LV Dimension and LV Function Between Baseline and 12 Months, as Assessed by Transthoracic Echocardiography

Variable	Paroxetine			Placebo			Paroxetine vs placebo	
	Baseline	12mo	Change	P value	Baseline	12mo	Change	P value
LV function								
EF (Simpson, biplane), %	41.0 (37.0 to 44.3)	50.0 (43.5 to 56.5)	8.0 (3.0 to 15.0)	0.005	43.0 (36.0 to 50.0)	54.0 (41.9 to 63.5)	7.1 (0.0 to 13.4)	0.008
GLS, %	12.4 (10.2 to 13.8)	15.2 (12.8 to 17.4)	3.2 (1.2 to 3.9)	<0.001	11.8 (10.7 to 13.5)	14.7 (14.1 to 17.6)	2.1 (1.0 to 4.2)	<0.001
LV dimensions								
End-diastolic diameter, mm	51.0 (47.0 to 54.0)	53.0 (47.5 to 55.5)	3.0 (-2.0 to 6.0)	0.038	51.0 (45.8 to 53.2)	49.0 (45.5 to 56.5)	3.0 (-5.0 to 4.0)	0.553
End-diastolic volume, mL	142.0 (114.8 to 153.8)	119.1 (105.5 to 148.0)	-2.7 (-29.7 to 15.9)	0.551	114.5 (102.0 to 128.0)	112.0 (89.9 to 137.2)	-16.5 (-18.9 to 9.5)	0.126

Data are presented as stratified by allocated study drug according to the intention-to-treat principle. Data are expressed as median (25%–75%). EF indicates ejection fraction; GLS, global longitudinal strain; and LV, left ventricular.

with anterior STEMI were randomly assigned to the experimental or the control group between October 26, 2017, and September 21, 2020. At 1 year, clinical and echocardiographic follow-up was complete in 100% and 80% of patients, respectively. The mean age of the patients was 61.8±12.6 years, and 41 (82%) were men. Demographic and clinical baseline characteristics have been reported previously.⁴ At 1 year, there were no significant differences between the experimental and the control groups with regard to antiplatelet or antithrombotic treatment, nor with regard to treatment with β blockers (81% versus 82%; $P>0.999$), renin-angiotensin system inhibitors (71% versus 82%; $P=0.49$), or angiotensin receptor–neprilysin inhibitors (14% versus 5%; $P=0.35$). Between baseline and follow-up at 1 year, mean LVEF and global longitudinal strain improved in both the experimental group and the control group, with no significant difference between the 2 treatment arms (Table). There were no differences in the change in LV dimensions and volumes between the 2 treatment groups, nor were there any differences in parameters of diastolic dysfunction between the 2 treatment arms. At 1 year, all study participants were alive and in New York Heart Association functional class I or II. One patient in each group had a hospitalization for heart failure. Two patients in the placebo group underwent transcatheter edge-to-edge mitral repair. One patient in the experimental arm underwent modified endoventricular circular plasty (Dor procedure). Four patients in the experimental group and 6 patients in the control group underwent implantation of an internal cardioverter-defibrillator. In this double-blind, placebo-controlled, randomized clinical trial, the extent of LVEF recovery and improvement of global longitudinal strain 1 year after anterior STEMI was comparable in patients treated with a 3-month course of paroxetine or placebo. A greater reduction in late gadolinium enhancement in patients in the experimental compared with the control group documented at 12 weeks by means of cardiac magnetic resonance imaging did not translate into differences in echocardiographic or clinical outcomes at 1 year. Both early revascularization and installation of guideline-directed heart failure treatment may have attenuated a potential effect of GRK2 inhibition as an add-on therapy. The reliability of the reported findings is limited by the modest sample size. In addition, reduction of LVEF at baseline was only moderate, thus attenuating the potential effect of paroxetine on LVEF recovery. In contrast to the assessment at 12 weeks, LV function at 1 year was assessed by use of echocardiography and not by magnetic resonance imaging. Moreover, both LVEF and global longitudinal strain provide an aggregate estimate of LV function, but may not be sensitive enough to assess differences in LV remodeling at a more granular level. Furthermore, GRK2 signaling levels were not

measured in this study. The CARE-AMI study documented no effect of paroxetine on LVEF recovery at 1 year in patients with STEMI.

ARTICLE INFORMATION

Received April 5, 2022; accepted June 21, 2022.

Registration: URL: <https://clinicaltrials.gov>; Unique identifier: NCT03274752.

Affiliations

Department of Cardiology, Inselspital, Bern University Hospital (T.P., B.B., M.F., R.V., N.R., S.W., S.S., G.C.S., L.H., J.L., S.D.) and Clinical Trials Unit (F.B.B., S.L.), University of BernSwitzerland.

Sources of Funding

The trial was an investigator-initiated study supported by dedicated grants from the Clinical Trial Unit, University of Bern, and the Gottfried und Julia Bangerter-Rhyner-Stiftung. The funding sources had no role in the design of the study, data collection, data monitoring, data analysis, data interpretation, writing of the report, and the decision to submit. The first and last authors (Drs Pilgrim and Dobner), as well as the trial statistician (Dr Babongo Bosombo), had full access to all the data in the study and assume final responsibility for the decision to submit for publication.

Disclosures

Relationships with industry: Dr Pilgrim reports research grants to the institution from Edwards Lifesciences, Boston Scientific, and Biotronik; personal fees from Biotronik, Boston Scientific, HighLife SAS, Abbott, and Medtronic outside of the submitted work. Dr Windecker reports research and educational grants to the institution from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Johnson&Johnson, Medtronic, Querbet,

Polares, Sanofi, Terumo, and Sinomed. Dr Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/executive committee group of several investigated-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland. All other authors have no potential conflicts of interest to disclose. S Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific, Abbott and Guerbet AG as well as consulting fees from BTG/Boston Scientific and Teleflex outside the submitted work.

REFERENCES

1. Pfeleger J, Gresham K, Koch WJ. G protein-coupled receptor kinases as therapeutic targets in the heart. *Nat Rev Cardiol*. 2019;16:612–622. doi: [10.1038/s41569-019-0220-3](https://doi.org/10.1038/s41569-019-0220-3)
2. Woodall MC, Woodall BP, Gao E, Yuan A, Koch WJ. Cardiac fibroblast GRK2 deletion enhances contractility and remodeling following ischemia/reperfusion injury. *Circ Res*. 2016;119:1116–1127. doi: [10.1161/CIRCRESAHA.116.309538](https://doi.org/10.1161/CIRCRESAHA.116.309538)
3. Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, Tesmer JJG, Koch WJ. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. *Sci Transl Med*. 2015;7:277ra31. doi: [10.1126/scitranslmed.aaa0154](https://doi.org/10.1126/scitranslmed.aaa0154)
4. Pilgrim T, Vollenbroich R, Deckarm S, Gräni S, Dobner S, Stark AW, Erne SA, Babonog Bosombo F, Fischer K, Stortecky S, et al. Effect of paroxetine-mediated G-protein receptor kinase 2 inhibition vs placebo in patients with anterior myocardial infarction: a randomized clinical trial. *JAMA Cardiol*. 2021;6:1171–1176. doi: [10.1001/jamacardio.2021.2247](https://doi.org/10.1001/jamacardio.2021.2247)